{"changeSha256":"9b98263c213335978e06882bd955987086462cc481c5fc4b551aa0bdb4adf39c","changedAt":"2026-09-15","changedFields":[{"after":"FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.","before":"A peptide named in FDA compounding-risk and DOJ enforcement records.","field":"Profile summary"},{"after":"FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.","before":"FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.","field":"Evidence note"},{"after":"fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024","before":"fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement","field":"Cited source records"},{"after":"name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024","before":"name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; evidenceNote: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/cjc-1295/versions/2/","version":2},"id":"profile:cjc-1295:v2","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"corrected","notice":"We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form.","peptideSlugs":["cjc-1295"],"previousChangeEvent":null,"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/cjc-1295/versions/1/","version":1},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-cjc-1295-briefing-2024","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024","url":"https://www.fda.gov/media/183819/download","verifiedAt":"2026-09-15"}],"subject":{"slug":"cjc-1295","type":"profile"}}